CoHort of STEMI Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Hospices Civils de Lyon
- Enrollment
- 1,204
- Locations
- 1
- Primary Endpoint
- Change in Troponin
Study Overview
Brief Summary
Ischemic heart disease is the leading cause of mortality in industrialized countries. ST elevated acute myocardial infarction is one of its most frequent and deadly manifestation. In the last 20 years, STEMI mortality has been reduced by 50% with the advent of timely reperfusion (primary percutaneous intervention) and significant progression in pharmacologic intervention.
However, death and heart failure incidence after STEMI remain elevated: up to 20% at one year.
Also, therapeutic management following international guidelines is standardized toward a "one-size fits all" therapeutic management.
In order to continue improving myocardial infarction outcomes, there is a need to better understand and individualize therapeutic targets such myocardial reperfusion injury, post reperfusion inflammation, adverse left ventricular (LV) remodeling ....
This knowledge will allow us to propose new therapeutic strategies and in the long run strive towards personalized medicine.
The aim objective of this cohort of STEMI patients is to identify new biological markers of injury and prognosis.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age> 18 years
- •Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
- •Primary PCI within 12 hours of symptoms onset.
Exclusion Criteria
- •Diagnosis of STEMI not confirmed by angiography
- •Refusal to participate in the study or to sign the consent
- •Inability to give information to the subject about the study
- •Lack of medical social coverage
- •Deprivation of civil rights
Outcomes
Primary Outcomes
Change in Troponin
Time Frame: Day 0
Dosage of Troponin at hospital admission and 4 hours after Percutaneous coronary intervention (PCI)
Change in Creatine Kinase
Time Frame: Day 0
Dosage of Creatine Kinase at hospital admission and 4 hours after PCI
Secondary Outcomes
- Left ventricular ejection fraction (LVEF)(24 hours after PCI (Day 1))
- New York Heart Association (NYHA) Class(at admission (Day 0))